These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 32131897)

  • 1. Levofloxacin-ceftazidime administration regimens combat Pseudomonas aeruginosa in the hollow-fiber infection model simulating abnormal renal function in critically ill patients.
    Zhao L; Li X; He X; Jian L
    BMC Pharmacol Toxicol; 2020 Mar; 21(1):20. PubMed ID: 32131897
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The combination of meropenem and levofloxacin is synergistic with respect to both Pseudomonas aeruginosa kill rate and resistance suppression.
    Louie A; Grasso C; Bahniuk N; Van Scoy B; Brown DL; Kulawy R; Drusano GL
    Antimicrob Agents Chemother; 2010 Jun; 54(6):2646-54. PubMed ID: 20368395
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Meropenem-Tobramycin Combination Regimens Combat Carbapenem-Resistant Pseudomonas aeruginosa in the Hollow-Fiber Infection Model Simulating Augmented Renal Clearance in Critically Ill Patients.
    Yadav R; Bergen PJ; Rogers KE; Kirkpatrick CMJ; Wallis SC; Huang Y; Bulitta JB; Paterson DL; Lipman J; Nation RL; Roberts JA; Landersdorfer CB
    Antimicrob Agents Chemother; 2019 Dec; 64(1):. PubMed ID: 31636062
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro pharmacokinetics/pharmacodynamics of continuous ceftazidime infusion alone and in combination with colistin against Pseudomonas aeruginosa biofilm.
    Gómez-Junyent J; Murillo O; Yu HH; Azad MAK; Wickremasinghe H; Rigo-Bonnin R; Benavent E; Ariza J; Li J
    Int J Antimicrob Agents; 2021 Feb; 57(2):106246. PubMed ID: 33253904
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacodynamics of ceftazidime administered as continuous infusion or intermittent bolus alone and in combination with single daily-dose amikacin against Pseudomonas aeruginosa in an in vitro infection model.
    Cappelletty DM; Kang SL; Palmer SM; Rybak MJ
    Antimicrob Agents Chemother; 1995 Aug; 39(8):1797-801. PubMed ID: 7486921
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Substantial Impact of Altered Pharmacokinetics in Critically Ill Patients on the Antibacterial Effects of Meropenem Evaluated via the Dynamic Hollow-Fiber Infection Model.
    Bergen PJ; Bulitta JB; Kirkpatrick CMJ; Rogers KE; McGregor MJ; Wallis SC; Paterson DL; Nation RL; Lipman J; Roberts JA; Landersdorfer CB
    Antimicrob Agents Chemother; 2017 May; 61(5):. PubMed ID: 28264846
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of different renal function on antibacterial effects of piperacillin against Pseudomonas aeruginosa evaluated via the hollow-fibre infection model and mechanism-based modelling.
    Bergen PJ; Bulitta JB; Kirkpatrick CM; Rogers KE; McGregor MJ; Wallis SC; Paterson DL; Lipman J; Roberts JA; Landersdorfer CB
    J Antimicrob Chemother; 2016 Sep; 71(9):2509-20. PubMed ID: 27231278
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination treatment with meropenem plus levofloxacin is synergistic against Pseudomonas aeruginosa infection in a murine model of pneumonia.
    Louie A; Liu W; VanGuilder M; Neely MN; Schumitzky A; Jelliffe R; Fikes S; Kurhanewicz S; Robbins N; Brown D; Baluya D; Drusano GL
    J Infect Dis; 2015 Apr; 211(8):1326-33. PubMed ID: 25362196
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Combination of Fosfomycin plus Meropenem Is Synergistic for Pseudomonas aeruginosa PAO1 in a Hollow-Fiber Infection Model.
    Drusano GL; Neely MN; Yamada WM; Duncanson B; Brown D; Maynard M; Vicchiarelli M; Louie A
    Antimicrob Agents Chemother; 2018 Dec; 62(12):. PubMed ID: 30249700
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Optimization and Evaluation of Piperacillin-Tobramycin Combination Dosage Regimens against Pseudomonas aeruginosa for Patients with Altered Pharmacokinetics via the Hollow-Fiber Infection Model and Mechanism-Based Modeling.
    Yadav R; Rogers KE; Bergen PJ; Bulitta JB; Kirkpatrick CMJ; Wallis SC; Paterson DL; Nation RL; Lipman J; Roberts JA; Landersdorfer CB
    Antimicrob Agents Chemother; 2018 May; 62(5):. PubMed ID: 29463528
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro efficacy of various antibiotic combinations against Pseudomonas aeruginosa isolates.
    Nazli E; Zer Y; Eksi F
    J Int Med Res; 2015 Apr; 43(2):217-25. PubMed ID: 25547417
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluating Mono- and Combination Therapy of Meropenem and Amikacin against Pseudomonas aeruginosa Bacteremia in the Hollow-Fiber Infection Model.
    Avent ML; McCarthy KL; Sime FB; Naicker S; Heffernan AJ; Wallis SC; Paterson DL; Roberts JA
    Microbiol Spectr; 2022 Jun; 10(3):e0052522. PubMed ID: 35442072
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [In vitro activity of ceftazidime-avibactam combined with colistin against extensively drug-resistant Pseudomonas aeruginosa].
    Mei Q; Geng S; Fang X; He Y; Liu L; Xu M; Zhu C; Pan A
    Zhonghua Wei Zhong Bing Ji Jiu Yi Xue; 2019 Oct; 31(10):1212-1218. PubMed ID: 31771717
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Simulated Intravenous versus Inhaled Tobramycin with or without Intravenous Ceftazidime Evaluated against Hypermutable Pseudomonas aeruginosa via a Dynamic Biofilm Model and Mechanism-Based Modeling.
    Bilal H; Tait JR; Lang Y; Zhou J; Bergen PJ; Peleg AY; Bulitta JB; Oliver A; Nation RL; Landersdorfer CB
    Antimicrob Agents Chemother; 2022 Mar; 66(3):e0220321. PubMed ID: 35041509
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bactericidal activity of ceftazidime against Pseudomonas aeruginosa under conditions simulating serum pharmacokinetic.
    Shah PM
    J Antimicrob Chemother; 1981 Sep; 8 Suppl B():135-40. PubMed ID: 19802977
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro and in vivo synergy of levofloxacin or amikacin both in combination with ceftazidime against clinical isolates of Pseudomonas aeruginosa.
    Piccoli L; Guerrini M; Felici A; Marchetti F
    J Chemother; 2005 Aug; 17(4):355-60. PubMed ID: 16167512
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synergism between tobramycin and ceftazidime against a resistant Pseudomonas aeruginosa strain, tested in an in vitro pharmacokinetic model.
    den Hollander JG; Horrevorts AM; van Goor ML; Verbrugh HA; Mouton JW
    Antimicrob Agents Chemother; 1997 Jan; 41(1):95-100. PubMed ID: 8980762
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of antibiotic sequence on combination regimens against Pseudomonas aeruginosa in a multiple-dose, in vitro infection model.
    Zelenitsky SA; Iacovides H; Harding GK; Ariano RE
    Diagn Microbiol Infect Dis; 2004 May; 49(1):67-70. PubMed ID: 15135504
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of in vitro synergy between vertilmicin and ceftazidime against Pseudomonas aeruginosa using a semi-mechanistic pharmacokinetic/pharmacodynamic model.
    Zhuang L; Sy SK; Xia H; Singh RP; Mulder MB; Liu C; Derendorf H
    Int J Antimicrob Agents; 2015 Feb; 45(2):151-60. PubMed ID: 25465523
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of resistance in wild-type and hypermutable Pseudomonas aeruginosa strains exposed to clinical pharmacokinetic profiles of meropenem and ceftazidime simulated in vitro.
    Henrichfreise B; Wiegand I; Luhmer-Becker I; Wiedemann B
    Antimicrob Agents Chemother; 2007 Oct; 51(10):3642-9. PubMed ID: 17682103
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.